Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Conditions associated with menopause represent a huge market, yet the R&D pipeline has long been slim, despite the well-known drawbacks of marketed hormone replacement therapies. But new approaches with a tissue-selective estrogenic effect are emerging: Shionogi’s Osphena for menopause-related sexual dysfunction broke the long drought in NME approvals, and Pfizer’s broad NDA for bazedoxifene/conjugated estrogens is under review. Emerging companies like EndoCeutics are exploring new hormonal approaches.

Advertisement

Related Content

Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
Pfizer’s Duavee Approved For Hot Flashes, Osteoporosis Prevention
Noven Gains Brisdelle Approval Over Advisory Committee Concerns
Women’s Health: Moving Beyond Gynecology To Sexuality
Making A Market In Women’s Health: Endometriosis, Fibroids Emerge As Rx Targets
Regenerating Interest In Novel Drugs For Postmenopausal Osteoporosis
Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses
Wyeth’s Viviant “Approvable” For Osteoporosis
Wyeth Pushes Back NDA Filing Timeline For Aprela For Vasomotor Symptoms
Prempro DTC Campaign Touts Lowest Approved Dose Of Hormone Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005362

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel